Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nova Eye Medical Ltd (EYE.AX)

Nova Eye Medical Ltd (EYE.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Nova Eye Medical Ltd 107 Rundle Street Kent Town Adelaide SA 5067 AUS

https://www.nova-eye.com P: +61 883620193 F: +61 883620193

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.

Key Statistics

Overview:

Market Capitalization, $K 42,725
Shares Outstanding, K 284,833
% of Institutional Shareholders 0.31%

Financials:

Annual Sales, $ 29,267 K
Annual Net Income, $ -9,059 K

Growth:

1-Year Return 42.86%
3-Year Return -23.08%
5-Year Return -55.22%
5-Year Revenue Growth 18.04%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.04
Most Recent Dividend 0.414 on 07/21/20
Next Ex-Dividends Date 07/21/20
Dividend Payable Date 07/29/20
Dividend Payout Ratio 0.00%
Most Recent Split 1-5 on 07/10/01

EYE.AX Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % -44.96%
Return-on-Assets % -32.13%
Profit Margin % -30.95%
Debt/Equity 0.13
Price/Sales 1.27
Price/Book 2.25
Book Value/Share 0.07
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar